Previous 10 | Next 10 |
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received a US$15 million milestone payment from AstraZeneca PLC (“ AstraZeneca ”) (L...
The following slide deck was published by HUTCHMED (China) Limited in conjunction with their 2021 Q4 earnings call. For further details see: HUTCHMED (China) Limited 2021 Q4 - Results - Earnings Call Presentation
Gainers: Atreca (NASDAQ:BCEL) +20%. Alignment Healthcare (NASDAQ:ALHC) +16%. Puma Biotechnology (NASDAQ:PBYI) +15%. Humanigen (NASDAQ:HGEN) +13%. agilon health (NYSE:AGL) +8%. Losers: DBV Technologies (NASDAQ:DBVT) -22%. Ocugen (NASDAQ:OCGN) -20%. ...
HUTCHMED (China) Limited (HCM) Q4 2021 Earnings Conference Call March 03, 2022, 08:00 AM ET Company Participants Christian Hogg - Chief Executive Officer Hong Chen - Senior Vice President and Chief Commercial Officer, China Weiguo Su - Executive Director and Chief Scientific Officer Marek Kan...
Hutchmed (NASDAQ:HCM) has announced the retirement of its CEO Christian Hogg. Hogg has been with the company for almost 22 years, including 15 years as Executive Director and CEO. Weiguo Su, who has been with the firm for about 17 years, including about 10 years as Chief Scientific Officer an...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 03, 2022 (GLOBE NEWSWIRE) -- (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces: (a) the retirement of Mr. Christian Hogg after almost 22 years with t...
Hutchison China MediTech press release (NASDAQ:HCM): FY GAAP EPS of -$0.25 beats by $1.54. Revenue of $356.1M (+56.2% Y/Y) beats by $17.33M. For further details see: Hutchison China MediTech GAAP EPS of -$0.25 beats by $1.54, revenue of $356.1M beats by $17.33M
Oncology/Immunology revenues up 296% to $119.6 million, due to ELUNATE ® growth and the 2021 launches of SULANDA ® and ORPATHYS ® ; Positive SAVANNAH, CALYPSO and VIKTORY studies triggered five registration studies on ORPATHYS ...
Hutchmed (China) (NASDAQ:HCM) received approval to market fruquintinib (sold as Elunate in China) to treat metastatic colorectal cancer in the Macau Special Administrative Region. The approval follows the latest update to the provisions on new drug importation which a...
HONG KONG and FLORHAM PARK, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it has received approval to market fruquintinib (ELUNATE ® in China), a selective and po...
News, Short Squeeze, Breakout and More Instantly...
HUTCHMED (China) Limited Company Name:
HCM Stock Symbol:
NASDAQ Market:
HUTCHMED (China) Limited Website:
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that the New Drug Application (“NDA”) for tazemetostat for the treatment of adult pati...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 26, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM: HCM; SEHK:13) will be announcing its interim results for the six months ended June 30, 2024 on Wednesday, July 31, 2024 at 7:00 am Eastern Daylig...
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 24, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“ HUTCHMED ”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a R&D update in Shanghai, China, and via webcast on Tuesday, July 9, 2024. During t...